This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



RNATICS develops nucleic acid therapies targeting disease-causing RNAs in tissue resident macrophages via inhalation. The primary target are inflammatory lung diseases with fibrotic lesions induced by viral infections or volatile toxic substances. For the lead candidate RCS-21, an antisense oligonucleotide against miR-21 coupled to a macrophage-targeting moiety, IND-enabling work is ongoing, and we aim to begin first-in-human clinical trials next year.

We're bringing you

  • Startup spotlight pitch competition